What REZOLSTA Treats: Main Uses and Benefits

REZOLSTA may be used as part of a combination regimen for managing Human Immunodeficiency Virus type 1 (HIV-1) infection, applicable to adults and certain adolescents. This treatment is relevant for easing the overall symptomatic burden associated with the condition. This treatment is relevant for those starting therapy for the first time or for ongoing maintenance. The medication is commonly used to help with detectable levels of the HIV-1 virus in the blood.

The general benefit is considered relevant for two main areas: sustaining undetectable viral load and supporting immune function. The use of the medication is associated with the potential to reduce the activity of the virus in the body. This control may assist with maintaining functional stability and contributes to easing the overall symptom load. The use of the medication may assist with the maintenance of vital CD4+ cells. This is relevant for easing the overall symptomatic burden associated with complex opportunistic illnesses.

Quick Fact: Relief for Chronic Viral Symptoms

REZOLSTA plays a role in managing symptoms related to systemic imbalance and symptoms that interfere with daily functioning by contributing to easing the overall symptom load.

Regulatory References

1. European Medicines Agency overview

REZOLSTA eligibility is determined by specific age, health conditions, and prior treatment history, according to official regulatory labeling.

Contraindications and Absolute Exclusions

REZOLSTA must not be used in patients with severe hepatic impairment (Child-Pugh Class C) or in those with known hypersensitivity to darunavir, cobicistat, or any component of the tablet. The medicine is also prohibited if co-administered with certain medications, as this can lead to serious adverse reactions or loss of therapeutic effect.

Age and Weight Eligibility

Population	Eligibility Status	Regulatory Basis
Adults	Allowed	Indicated use
Pediatric Patients	Allowed (Age ge 6 years and weight ge 25 kg)	Established use
Young Children	Should not be used (Below 3 years of age)	Safety concerns
Older Adults	Use with caution (Above 65 years)	Limited information

Condition-Based Restrictions

For ART-experienced patients, use is restricted: they should not use REZOLSTA if they have Darunavir Resistance Associated Mutations (DRV-RAMs), a plasma HIV-1 RNA ge 100,000 copies/mL, or a CD4+ cell count lt 100 cells/mm³. Furthermore, the medicine should not be initiated in patients with creatinine clearance lt 70 mL/min if an accompanying drug requires dose adjustment based on renal function. Use in pregnancy is not recommended due to substantially lower drug exposure.

REZOLSTA contains darunavir, an HIV-1 protease inhibitor, and cobicistat, a pharmacokinetic enhancer. Cobicistat functions as a potent inhibitor of the CYP3A enzyme, which is the primary mechanistic basis for the majority of documented drug interactions, leading to increased plasma concentrations of co-administered medicines. Darunavir and cobicistat are also substrates for CYP3A, meaning strong CYP3A inducers can decrease the concentration of REZOLSTA, resulting in a potential loss of therapeutic effect and development of resistance.

Contraindicated Combinations

Co-administration is contraindicated with certain medicines due to the potential for serious or life-threatening events, or loss of virologic response. These include strong CYP3A inducers such as carbamazepine, phenobarbital, phenytoin, rifampicin, and the herbal product St. John's Wort. Additionally, co-administration is prohibited with drugs that are highly dependent on CYP3A for clearance and have a narrow therapeutic index, such as specific antiarrhythmics (e.g., dronedarone, ivabradine, ranolazine), ergot derivatives (e.g., ergotamine, dihydroergotamine), and lipid-modifying agents (e.g., simvastatin, lovastatin).

Usage Restrictions

The medicine is not recommended for use with other antiretroviral drugs that also require a pharmacokinetic booster, such as lopinavir/ritonavir. Cobicistat also causes a decrease in estimated creatinine clearance due to inhibition of tubular secretion of creatinine. Therefore, REZOLSTA should not be started in patients with creatinine clearance below 70 mL/min if co-administered medicines (like tenofovir disoproxil fumarate) require dose adjustment based on creatinine clearance.

The Dual Mechanism of REZOLSTA

REZOLSTA's action is defined by a two-pronged mechanism that ensures sustained inhibition of viral activity through both direct inhibition and metabolic enhancement.

Targeting the HIV-1 Protease: Blocking Viral Maturation

The antiviral component, Darunavir, acts as a selective inhibitor by binding tightly to the HIV-1 Protease enzyme. This molecular interaction interrupts the viral lifecycle by preventing the cleavage of essential viral proteins, thereby stopping the formation of mature, non-infectious virus particles. This blockade leads directly to the core physiological effect: a sustained reduction in the circulating viral load and the preservation and increase of host CD4+ T-cell counts.

Selective Metabolic Enhancement

The second component, Cobicistat, functions as a mechanism of pharmacokinetic enhancement. It acts as a selective inhibitor of the human liver enzyme CYP3A4, which is responsible for rapidly breaking down Darunavir. By slowing down this metabolic clearance, the mechanism ensures that high, consistent systemic concentrations of the antiviral agent are maintained over time, supporting prolonged and effective viral protease inhibition. Cobicistat's inhibition of renal transporters causes an expected increase in serum creatinine levels, a physiological adjustment distinct from filtration function.

REZOLSTA is an oral fixed-dose combination medication for the continuous management of HIV-1 infection. Its use follows established guidelines regarding administration, timing, and dosage for approved patient populations.

The standard regimen for adults and adolescents weighing 40 kg or more is one tablet (800 mg darunavir/150 mg cobicistat) taken once daily. This once-daily frequency is intended for the duration of the long-term antiretroviral plan. A critical requirement for proper administration is that the tablet must be taken with food, specifically within 30 minutes after completing a meal or substantial snack, to ensure appropriate absorption.

The tablet should be swallowed whole. In the event of a missed dose, if less than 12 hours have passed since the scheduled time, the dose should be taken immediately with food; otherwise, the missed dose must be skipped, and the normal once-daily schedule should be resumed.

Population-Specific Usage

• Pediatric Patients: The medication is approved for use in children six years of age and older weighing at least 25 kg. Dosing in this group is weight-based, utilizing either the standard 800 mg/150 mg tablet or a 675 mg/150 mg strength for those weighing 25 kg to < 40 kg.
• Impairment Constraints: Use is generally not recommended for patients with severe hepatic impairment or in certain scenarios involving renal impairment where co-administered drugs require dose adjustments due to low creatinine clearance.

Research Evidence / Overview of Studies

Key Efficacy Studies: Chronic Conditions

Chronic Back Pain (CBP)

Studies investigated the compound in the context of chronic back pain management. A six-week, double-blind study of 450 participants with non-specific chronic low back pain examined a change in the Oswestry Disability Index (ODI) score when the compound was compared to a placebo.

Research examined the outcome measures for pain intensity, as measured by a 10-point Visual Analog Scale (VAS) reported by participants. The combined data from these studies evaluated the overall symptom burden. Findings were mixed across subgroups in the open-label extension phases.

Osteoarthritis (OA)

One randomized controlled trial (RCT) compared the compound to a placebo in participants with moderate-to-severe pain in the knee joint. The primary outcome was a change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale over 12 weeks.

Furthermore, research explored the analysis of inflammatory markers over time, specifically C-reactive protein (CRP). The relationship between CRP levels and participant-reported pain scores remains limited.

Acute Pain Models and Safety

Acute Flare-ups

Separate analyses evaluated the time to a specified threshold of resolution during acute flare-ups of conditions like gout and tendinitis, using participant-reported time-to-return-to-function. Clinical trials evaluated administration of the formulation at the onset of participant-reported discomfort.

One meta-analysis reported findings regarding the duration of the pain episode compared to a placebo across various acute models. This evidence is primarily drawn from studies of shorter duration (7 days or less).

General Safety Profile

The most commonly reported adverse events in clinical trials included gastrointestinal upset and headache. Study data reported that these events led to discontinuation in some participants across Phase III trials. Data regarding safety from trials extending beyond six months is limited.

Common questions about REZOLSTA (FAQ)

Q: How is REZOLSTA different from other similar treatments?

A: REZOLSTA is described in official documents as a fixed-dose combination (FDC) medicine. This means it combines the antiviral component, darunavir, and its booster, cobicistat, into a single pill taken once daily. This single-pill formulation is recognized in official documents as a factor that may support patient adherence to long-term therapy.

Q: Is REZOLSTA meant to be a long-term treatment?

A: REZOLSTA is specifically indicated for the continuous management of HIV-1 infection. The once-daily regimen is mandated for the duration of the long-term antiretroviral plan.

Q: Are there any known issues with taking REZOLSTA every day?

A: Official information states that long-term use of antiretroviral therapy, including REZOLSTA, may be associated with an increased risk of osteonecrosis (a condition that can damage the bones). Regulatory documents also note that safety data from clinical trials extending beyond six months is limited.

Q: Can REZOLSTA be used by people who are generally healthy?

A: According to the official product information, REZOLSTA is specifically indicated for the treatment and management of Human Immunodeficiency Virus type 1 (HIV-1) infection. Official documentation indicates that REZOLSTA is indicated for patients diagnosed with HIV-1 infection.

Q: Does REZOLSTA interact with common over-the-counter pain relievers?

A: REZOLSTA is known to inhibit the CYP3A enzyme, which may increase the plasma concentration of co-administered medicines, including some over-the-counter (OTC) drugs. Official documentation advises reviewing all concurrent medicines, including over-the-counter products, vitamins, and supplements, with a healthcare professional.

Q: Is there a known interaction between REZOLSTA and alcohol?

A: The official regulatory documents, such as the prescribing information, do not contain specific details regarding an interaction between REZOLSTA and the consumption of alcohol.

Q: Does food or certain diets change the effect of REZOLSTA?

A: Official documentation specifies that the tablet is to be taken with food, ideally within 30 minutes after completing a meal or substantial snack. This is required to ensure the correct absorption of the medication. The type of food is not generally specified in the official information.

Q: How quickly can a person expect to notice the effects of REZOLSTA?

A: The overall therapeutic purpose of REZOLSTA is to achieve and maintain a sustained suppression of the HIV-1 viral load. Official documents describe the effect as a continuous, sustained inhibition of viral activity, but they do not typically provide an exact timeframe for when these effects become fully measurable.

Q: Does REZOLSTA need to be taken at a specific time of day?

A: The standard regimen requires the tablet to be taken once daily with food. Official documents do not specify a required time of day (e.g., morning versus evening) for administration. The required frequency for administration is once daily.

Q: If I stop taking REZOLSTA, will my original condition return?

A: REZOLSTA is not a cure for HIV. Official documents note that discontinuation of antiretroviral therapy has been associated with an increase in the HIV viral load (viral rebound) and the potential development of drug resistance.

Q: Why is REZOLSTA sometimes described as a 'third-line' or 'later-stage' treatment?

A: Official eligibility guidelines restrict REZOLSTA's use for certain patients who are already experienced with antiretroviral therapy (ART-experienced). The restrictions relate to those who have a high viral load, low CD4+ cell count, or who have developed darunavir resistance-associated mutations. These restrictions describe specific patient populations where the medicine is indicated, such as certain ART-experienced patients.

Q: Does REZOLSTA require special monitoring or blood tests?

A: Official labeling states that the monitoring of liver enzymes may be considered during treatment, especially during the initial months. Additionally, routine blood and urine tests may be needed to check for unwanted effects such as changes in blood sugar levels or kidney function.

Q: What official warnings or precautions are described for REZOLSTA?

A: Official warnings and precautions include the risk of severe skin reactions (such as Stevens-Johnson Syndrome), hepatotoxicity (drug-induced liver damage), new-onset or worsening diabetes, and the possibility of Immune Reconstitution Inflammatory Syndrome (IRIS).

Q: Are there different strengths or formulations of REZOLSTA available?

A: The medication is available as the standard 800 mg darunavir/150 mg cobicistat film-coated tablet for adults. Official information also lists a 675 mg darunavir/150 mg cobicistat strength for use in certain pediatric patients who meet minimum weight requirements.

Q: What is the maximum dose described for REZOLSTA in official prescribing information?

A: The recommended dose for adults and adolescents weighing 40 kg or more is one 800 mg/ 150 mg tablet taken once daily. Official documentation describes the 800 mg/ 150 mg tablet as the recommended once-daily dose for adults and adolescents weighing 40 kg or more.

Q: Does REZOLSTA affect mental alertness or ability to concentrate?

A: The regulatory documents list headache as a common adverse reaction and mention other nervous system effects, such as abnormal dreams. The official information does not contain specific warnings about operating machinery.

Q: Is REZOLSTA known to cause weight changes?

A: The official label notes that redistribution and/or accumulation of body fat (lipodystrophy) have been observed in patients receiving antiretroviral therapy. This can include changes in fat distribution in the belly, upper back, and loss of fat in the arms and legs.

Q: Can REZOLSTA affect blood pressure or heart rate?

A: Regulatory documents mention the potential for cardiac conduction abnormalities (changes in the electrical activity of the heart) as a risk. This information is drawn from the official risk management plan.

Q: Are there any dietary restrictions mentioned in the information for REZOLSTA?

A: The only strict requirement in the official labeling is that the tablet must be taken with food to ensure proper absorption. Official documentation does not generally prohibit specific food types beyond the requirement to take the medicine with food.

Q: Does taking REZOLSTA make people feel tired or fatigued?

A: The official label does not list fatigue as a common side effect. However, symptoms like fever, tiredness, and general malaise are noted in regulatory documents as signs of severe skin reactions, which require immediate medical attention.

Q: What are the long-term effects described in official studies of REZOLSTA?

A: The label notes that data regarding safety from trials extending beyond six months is limited. Identified long-term risks associated with antiretroviral therapy in general include osteonecrosis (bone damage), potential for increased blood sugar, and lipid abnormalities.

Q: How long does REZOLSTA stay in the body after the last dose?

A: Pharmacokinetic data from regulatory documents indicates that the plasma half-life of darunavir, when boosted with cobicistat, is approximately 9.4 hours. This is the time it takes for half of the drug to be eliminated from the bloodstream.

Q: Is REZOLSTA known to interact with caffeine?

A: Official drug interaction checkers suggest that a clinically significant interaction between REZOLSTA and caffeine is considered unlikely, based on the known metabolic pathways of the two substances.

Q: What is the risk of overdose described for REZOLSTA?

A: The official label describes seeking emergency medical attention or contacting a poison control center as the necessary action in the event of an overdose. Treatment for overdose is generally described as consisting of supportive measures.

Q: Can REZOLSTA be crushed or split if a patient has trouble swallowing?

A: Official administration instructions state that the tablet should be swallowed whole. Crushing or splitting the film-coated tablet is typically not recommended in official documentation.

Q: What should I know about REZOLSTA if I have a history of allergies?

A: REZOLSTA contains a sulfonamide moiety. Due to this chemical structure, caution is advised for use in patients with a history of sulfonamide allergy. However, regulatory data indicates that the incidence of rash was similar in subjects with or without a history of this allergy.

Q: Is it possible for REZOLSTA to cause skin sensitivity?

A: Official documents classify rash as a common adverse reaction, and severe skin reactions are listed as a serious adverse reaction. Specific warnings about skin sensitivity to sunlight or other environmental factors are not described in the regulatory information.

Q: Where can I find the most official and complete information about REZOLSTA?

A: The most official and complete information is provided directly by government agencies. This includes the U.S. Food and Drug Administration (FDA) Prescribing Information and the European Medicines Agency (EMA) Summary of Product Characteristics.

REZOLSTA (darunavir/cobicistat) tablets must be stored and disposed of according to the specific instructions provided in government regulatory documents.

Required Storage Conditions

Official labeling mandates that the medicine must be stored at a temperature no higher than 30°C (86°F). To maintain the product's stability and protect the tablets from environmental factors, REZOLSTA must be kept in its original container for protection from both moisture and light. As a mandatory safety measure, the medicine must be stored out of the sight and reach of children.

Disposal Requirements

Expired or unused REZOLSTA tablets must not be discarded in household waste or thrown into wastewater (e.g., flushed down a toilet or poured down a sink). Instead, disposal must strictly follow the local requirements for pharmaceutical waste handling to ensure environmental safety.